Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Oct 23, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new diagnostic tool called [18F]PSMA-1007, which helps doctors detect prostate cancer that may have come back after initial treatment. The trial aims to see how well this imaging method works in everyday medical care and how it can improve the management of prostate cancer for patients. By gathering real-world evidence, the researchers hope to provide insights that will help doctors optimize treatment decisions for men facing biochemical recurrence of prostate cancer.
To participate in this study, men between the ages of 65 and 74 who can give informed consent are eligible. Participants will undergo [18F]PSMA-1007 PET imaging as part of their regular clinical care. It's important to note that those with any technical issues during the imaging process will not be included in the study. If you decide to join, you can expect to contribute valuable information that may help improve future prostate cancer diagnostics and treatments.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent
- • Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care
- Exclusion Criteria:
- • Technical Flaws in the acquisition protocol
About Heinrich Heine University, Duesseldorf
Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Düsseldorf, Nrw, Germany
Patients applied
Trial Officials
Frederik Lars Giesel, Prof. Dr., Medical Doctor
Study Chair
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported